We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Outcomes of Stem Cells for Cerebral Palsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02569775
Recruitment Status : Completed
First Posted : October 7, 2015
Last Update Posted : October 16, 2015
Sponsor:
Information provided by (Responsible Party):
Vinmec Healthcare System

Brief Summary:
The aim of this study is to assess the safety and effectiveness of autologous bone marrow mononuclear stem cells in patients with cerebral palsy.

Condition or disease Intervention/treatment Phase
Cerebral Palsy Biological: Autologous Bone Marrow Mononuclear Cells Phase 2

Detailed Description:
The aim of this study is to assess the safety and effectiveness of autologous bone marrow mononuclear stem cells in 40 patients with cerebral palsy at Vinmec International Hospital, Hanoi, Vietnam.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Outcomes of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy: A Self-Controlled Clinical Trial
Study Start Date : April 2014
Primary Completion Date : August 2015
Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Stem cell transplantation
2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
Biological: Autologous Bone Marrow Mononuclear Cells
Transplantation of Autologous Bone Marrow Mononuclear Cells



Primary Outcome Measures :
  1. Change in Total Score of Gross Motor Function Measure (GMFM)-88 [ Time Frame: 3 months and 6 months after transplantation ]
    GMFM-88

  2. Change in Gross Motor Function Measure (GMFM)-66 Percentile [ Time Frame: 3 months and 6 months after transplantation ]
    GMFM-66 percentile


Secondary Outcome Measures :
  1. Change in Muscle tone [ Time Frame: 3 months and 6 months after transplantation ]
    Muscle tone are assessed by Modified Ashworth Scale

  2. Number of adverse events [ Time Frame: Through study completion, an average of 6 months ]
    Examples of adverse events to look for: anaphylaxis, allergy, respiratory distress, fever, infections, vomit, epilepsy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cerebral palsy of any types caused by oxygen deprivation.

Exclusion Criteria:

  • Epilepsy
  • Hydrocephalus with ventricular drain
  • Coagulation disorders
  • Allergy to anesthetic agents
  • Severe health conditions such as cancer, failure of heart, lung, liver or kidney
  • Active infections

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02569775


Locations
Vietnam
Vinmec International Hospital
Hanoi, Vietnam
Sponsors and Collaborators
Vinmec Healthcare System
Investigators
Study Chair: Liem T Nguyen, MD., PhD. Vinmec Healthcare System

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Vinmec Healthcare System
ClinicalTrials.gov Identifier: NCT02569775     History of Changes
Other Study ID Numbers: TBG 001
First Posted: October 7, 2015    Key Record Dates
Last Update Posted: October 16, 2015
Last Verified: October 2015

Keywords provided by Vinmec Healthcare System:
Cerebral Palsy
Stem Cells

Additional relevant MeSH terms:
Paralysis
Cerebral Palsy
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Brain Damage, Chronic
Brain Diseases
Central Nervous System Diseases